Budesonide is a widely used glucocorticoid in clinical practice. Characterized by potent local anti-inflammatory activity and low systemic absorption, it is extensively indicated for multiple inflammatory disorders including bronchial asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pharyngolaryngitis, and enteritis. Compared with orally or intravenously administered corticosteroids, it boasts superior safety and a lower incidence of adverse reactions, yet it is not entirely free of side effects. Adverse reactions may still emerge following prolonged high-dose administration or improper medication techniques. Understanding its potential side effects and corresponding management strategies can effectively mitigate medication risks and ensure safe drug use.
I. Local Adverse Reactions: Most Common and Mild in Severity
Local adverse reactions predominantly occur at mucosal sites directly exposed to the drug, commonly seen with inhaled, nasal spray and buccal formulations. Most symptoms are mild and reversible, and standardized administration can drastically reduce their incidence.
1. Local Respiratory Reactions
This is the most typical side effect of inhaled budesonide. Many patients experience dry, itchy or slightly stinging throat and hoarseness after administration. This arises from persistent mucosal irritation induced by the corticosteroid, leading to mild local mucosal dehydration and minor dysbiosis of the local flora. Some individuals may also develop transient cough or a foreign body sensation in the throat, which generally manifests at the initial treatment stage and gradually subsides as tolerance develops with standardized continued use.
Failure to rinse the mouth promptly after dosing leaves residual drug in the throat, which suppresses local immunity and predisposes patients to oropharyngeal candidiasis, commonly known as thrush. Clinical manifestations include white plaques on the oral and pharyngeal lining accompanied by mild pain and discomfort during eating, with a relatively higher incidence in children.
2. Nasal Local Reactions
For budesonide nasal sprays prescribed for allergic rhinitis, frequent local adverse reactions include nasal dryness, nasal stinging, mild epistaxis and aggravated nasal congestion. Nasal mucosa is inherently delicate; irritation from spray droplets and steroid-induced mucosal dryness increase capillary fragility. Minor nosebleeds are particularly prevalent in dry autumn and winter seasons, which usually bleed minimally and stop quickly. A small subset of patients may also present mild allergy-like symptoms such as nasal pruritus and frequent sneezing.
3. Intestinal Local Reactions
Enteric-coated budesonide formulations for ulcerative colitis and Crohn's disease act directly on intestinal mucosa. A small number of patients may experience mild abdominal pain, abdominal distension, transiently increased bowel frequency and anal discomfort, mostly occurring during the initial adaptation phase and alleviating progressively as treatment continues.
II. Systemic Adverse Reactions: Mainly Associated with Long-Term High-Dose Use
Budesonide has low systemic bioavailability, resulting in minimal systemic side effects at conventional therapeutic doses. Systemic mild reactions may only occur with long-term overdose, metabolic disorders, or prolonged administration in children, the elderly and debilitated individuals, and such risks are far lower than those of conventional glucocorticoids.
1. Mild Endocrine and Metabolic Abnormalities
Prolonged high-dose treatment may slightly affect hypothalamic-pituitary-adrenal (HPA) axis function, causing mild adrenal suppression in very rare cases, though severe adrenal crisis seldom occurs. Excessive long-term use in children may lead to retarded growth manifested as slowed height gain, a major concern for guardians. Nevertheless, standard dosed administration exerts negligible impact on childhood growth, requiring only regular height monitoring.
In addition, mild sodium and water retention presenting as slight periorbital and facial edema may occur in some patients, alongside marginal elevation of blood glucose and lipid levels. Close glycemic monitoring is mandatory for patients with diabetes mellitus.
2. Effects on the Immune System
As glucocorticoids exert immunosuppressive effects, long-term use slightly attenuates bodily resistance, rendering patients more susceptible to upper respiratory tract infections, colds, skin infections and other infectious diseases with slightly slower recovery. However, such immunosuppression is very weak at standard therapeutic doses and does not significantly raise the risk of severe infection.
3. Musculoskeletal Effects
Prolonged uninterrupted high-dose administration may mildly impair calcium absorption and bone metabolism, leading to slight reduction in bone mineral density. Long-term use in middle-aged and elderly patients carries a potential elevated risk of osteoporosis, and an extremely small proportion of users may complain of myalgia and fatigue.
4. Psychiatric and Neurological Reactions
These adverse reactions have a very low incidence, mostly reported in sensitive individuals or long-term users. A small number of patients suffer from insomnia, vivid dreams, irritability, anxiety and poor concentration; children may present restlessness, increased crying and disturbed sleep, which resolve rapidly upon dose reduction or drug discontinuation.
III. Rare Severe Adverse Reactions
Such side effects are rarely encountered clinically, yet immediate drug withdrawal and medical consultation are required once they develop. Principal presentations include severe hypersensitivity reactions such as generalized rash, urticaria, laryngeal edema and dyspnea. Elevated intraocular pressure, glaucoma and cataracts occur in extremely rare cases (secondary to indirect ocular exposure from long-term nasal or inhaled administration). Isolated cases of severe gastrointestinal upset and mild liver function abnormalities have also been documented.
IV. Prevention and Evidence-Based Management of Adverse Reactions
Most side effects of budesonide can be effectively prevented via standardized administration, eliminating excessive anxiety. Core preventive measures are outlined below:
Standardize administration procedures. After using inhalers or receiving nebulized therapy, mouth rinsing and facial washing must be performed promptly to eliminate residual drug on oral and facial surfaces, which is critical for preventing oropharyngeal candidiasis and hoarseness. When applying nasal sprays, tilt the head slightly forward to prevent drug reflux into the throat and minimize local irritation.
Strictly follow physician instructions for medication. Do not arbitrarily increase dosage or prolong treatment duration. Use is subject to medical supervision for children, the elderly, pregnant women and patients with chronic illnesses, with regular follow-ups to assess therapeutic efficacy and physical status.
Targeted symptomatic management. Sipping warm water and saline nasal irrigation can relieve mild sore throat and nasal dryness. Mild thrush can be treated with topical antifungal ointments under medical guidance, with temporary dose reduction or interruption facilitating recovery. Height should be monitored regularly for pediatric patients; middle-aged and elderly long-term users may supplement calcium and vitamin D appropriately to counteract declining bone mineral density.
Indications for urgent medical attention. Prompt drug cessation and clinical consultation for treatment adjustment are required in case of persistent refractory hoarseness, recurrent epistaxis, severe abdominal pain, sustained insomnia and irritability, generalized rash, dyspnea or other abnormal manifestations after administration.
V. Conclusion
Overall, budesonide is a clinically common drug with excellent safety profile. Adverse reactions are mild and manageable under standard-dose standardized use, with severe side effects extremely uncommon. Most users only experience transient local irritation, preventable with simple care and proper administration techniques. Patients should not avoid treatment out of fear of side effects; arbitrary dose reduction or discontinuation often triggers recurrent exacerbations of underlying conditions including asthma, rhinitis and enteritis, worsening disease progression. Strict adherence to medical advice, rational medication and post-dose care can maximize risk avoidance and optimize therapeutic outcomes.
